Bayer : FY guidance confirmed after solid Q1 results – Pharma better, Consumer Health worse than expected
>EBITDA decline less pronounced than feared - At a group level, Bayer’s Q1 sales of € 13.8bn (-4.3%), was below our (€ 14.0bn) and the consensus estimates (€ 14.1bn), the group’s EBITDA of € 4,412m (-1.3%) came in stronger than we expected (€ 4,188m) and was 6.4% above the consensus. The group’s EBITDA decline vs Q1 2023 was driven by the Crop Science divisions, where a decrease in glyphosate-based herbicides and cost inflation weighed on earnings. On the back of the ...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.